Page 98 - Human Use News Today

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine has published results from a...

Positive Dupixent (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine Dupixent 300 mg weekly showed significant

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine has published results from a...

Daiichi Sankyo and AstraZeneca’s ENHERTU (trastuzumab deruxtecan) has secured approval in the European Union (EU) as a monotherapy to treat adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received an earlier trastuzumab-based regimen.

Drug is the first heart failure medication to provide mortality benefit across entire ejection fraction range - News - PharmaTimes

This Week in Washington: All Efforts Are on Funding the Government Through the Rest of the Fiscal Year...

Ebvallo™ is the first authorised allogeneic T-cell immunotherapy and has been approved for EU patients with relapsed or refractory EBV+ PTLD.

Positive Phase III study data has prompted the CHMP to recommend fenfluramine for seizures associated with Lennox-Gastaut syndrome.

Investegate announcements from AstraZeneca PLC, Imfinzi + Imjudo recommended for approvals in EU

L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...